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Abstract
Background: Gene copy number of complement component C4, which varies among individuals, may determine
the intrinsic strength of the classical complement pathway. Presuming a major role of complement as an effecter
in peptide-mediated inflammation and phagocytosis, we hypothesized that C4 genetic diversity may partially
explain the development of Graves’ disease (GD) and the variation in its outcomes.
Methods: A case-control study including 624 patients with GD and 160 healthy individuals were enrolled. CNV of
C4 isotypes (C4A and C4B) genes were performed by quantitative real-time polymerase chain reaction analysis.
Statistical comparison and identification of CNV of total C4, C4 isotypes (C4A and C4B) and C4 polymorphisms were
estimated according to the occurrence of GD and its associated clinical features.
Results: Individuals with 4, 2, and 2 copies of C4, C4A and C4B genes, especially those with A2B2 polymorphism
may associate with the development of GD (p = 0.001, OR = 10.994, 95% CI: 6.277-19.255; p = 0.008, OR = 1.732,
95% CI: 1.190-2.520; p = 2.420 × 10-5, OR = 2.621, 95% CI: 1.791-3.835; and p = 1.395 × 10-4, OR = 2.671, 95% CI:
1.761-4.052, respectively). Although the distribution of copy number for total C4, C4 isotypes as well as C4
polymorphisms did not associate with the occurrence of goiter, nodular hyperplasia, GO and myxedema, <2 copies
of C4A may associate with high risk toward vitiligo in patients with GD (p = 0.001, OR = 5.579, 95% CI:
1.659-18.763).
Conclusions: These results may be further estimated for its clinical application on GD and the vitiligo in patients
with GD.
Background
Graves’ disease (GD) is an organ-specific autoimmune
thyroid disease [1]. It has been known that multiple fac-
tors, including the host’s genetic factors as well as environ-
mental factors, contribute to the etiology and severity of
GD [2,3]. However, other forms of variation that might
affect gene expression should also be considered.
A new paradigm in human genetics is high frequencies
of interindividual variation in the copy number (CN) of
specific genomic DNA segments. Copy number variation
(CNV) loci often contain genes engaged in host-environ-
ment interactions, including those involved in immune
functions, which results in susceptibility or resistance to
autoimmune diseases [4-7], however, no significant asso-
ciation has been found between CNV and GD [6].
Complement component C4 (C4), located on chromo-
some 6q21.3, is encoded by 2 separate loci in the major
histocompatibility complex class III region and derives 2
functionally distinct C4A and C4B isoforms [8]. The
complement system is the main element of innate immu-
nity and is regarded as the first line of defense against
intrinsic and extrinsic antigens, leading to peptide-
mediated inflammation, opsonization leading phagocyto-
sis, the direct lysis of antigens [9]. Presuming a major
role of complement as an effecter in peptide-mediated
inflammation and phagocytosis, we hypothesized that C4
genetic diversity may partially explain the development
of GD as well as the variation in its outcomes. Here we
investigated the polymorphic variants of C4 that correlate
with predisposition to this disease.
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Methods
Patients and healthy individuals
A total of 624 patients (227 with GO and 397 without GO)
with a confirmed diagnosis of GD and an appropriate con-
trol group with 160 healthy volunteers from China Medi-
cal University Hospital in Taiwan were enrolled and
followed actively. All individuals provided informed con-
sent as approved by the ethics committee of China Medi-
cal University Hospital. For the patients, diagnosis of GD
and GO was followed the criteria set previously [10]. Full
medical record abstraction was conducted to obtain
demographics (age and gender); treatment and clinical fea-
tures are summarized in Table 1. For the healthy indivi-
duals, those with matched for gender according to the
female predominance of GD including 32 male (20.0%)
and 128 female (80.0%). Age was different in healthy
(27.4 ± 6.4 years) as compared to the patients with GD
(41.1 ± 12.9 years) (p = 1.96 × 10-34).
Genomic DNA extraction and quantification gene dosage
of C4A and C4B
Genomic DNA was extracted from peripheral blood fol-
lowing the manufactory’s suggestions (Qiagen). C4 gene
dosage was assessed by quantitative real-time TaqMan®
PCR analysis (Applied Biosystems) as described in the
previously published protocols with some modification
[11]. Real-time PCR analysis was performed in 96-well
optical plates on a 7900HT real-time PCR system
(Applied Biosystems). Primers and probes specific for
C4A, and C4B (common C4A and C4B forward primer
“C4F": 5’-GCA GGA GAC ATC TAA CTG GCT TCT-3’;
common C4A and C4B reverse primer “C4R": 5’-CCG
CAC CTG CAT GCT CCT-3’; probe “C4A“: FAM-ACC
CCT GTC CAG TGT TAG; probe “C4B“: FAM-ACC
TCT CTC CAG TGA TAC. TaqMan® Universal PCR
Master Mix, No AmpErase® uracil-DNA glycosylase
(ABI catalog number 4326614), VIC-conjugated Taq-
Man® RNase P control reagents (ABI catalog number
4316844), 250 nM of the respective FAM-conjugated
TaqMan® probes (C4A or C4B), the particular primers
(300 nM C4A or C4B) in distilled water was contained in
each of the distinct PCR batches. Appropriately predi-
luted genomic DNA (threshold cycle [CT] values for
RNase P between 24 and 30) was added before start. CN
of each target gene in each sample was determined from
three separated experiments. Thermal cycler conditions
were adjusted as follows: initial denaturation step for 10
minutes at 95°C; 40 cycles including denaturation for 15
seconds at 95 °C; and annealing/extension for 1 minute
for 60°C. The data were analyzed using SDS 2.3 software
(Applied Biosystems).
The CT value of RNase P, C4A or C4B was converted
into a raw gene dosage by the formula nRAWC4X = 2
(CTRNase P)-(CTC4X)+1, where C4X referred to C4A or C4B.
Raw gene dosages of positive controls selected from the
reference panel were plotted versus the actual gene
dosages, and the resulting calibration curve served for
determination of the actual copy number of unknown
samples of this particular run.
Statistical analysis
Statistical analysis was performed using the statistical
package PASW for Windows (version 18.0; SPSS Inc.).
The demographics of patients and healthy individuals
were analyzed by the chi-square analysis. For those with
2 × 2 contingency tables, differences in the incidence of
individuals with C4 gene CNs above and below the
median or C4A-C4B polymorphisms between patients
with or without indicated feature were evaluated using
Fisher’s exact test. For those above 2 × 2 contingency
tables, differences in the incidence of individuals with
C4 gene CNs above and below the median or C4A-C4B
polymorphisms between patients with or without indi-
cated feature were evaluated using Fisher’s exact test,
and the two-tailed p value was estimated by 100,000
Monte Carlo simulations with 99% confidence intervals
(CI) (99% confidence for the simulation result). Odds
ratios (ORs) and 95% CIs were estimated from logistic
regression models adjusting for confounding variables as
shown in Table 1.
Results
CNV of C4 genes is associated with susceptibility to GD
The distribution of copy number for total C4, C4 isotypes
as well as C4 polymorphisms according to the presence
of GD is shown in Table 2. No individuals had a full defi-
ciency of C4 alleles. After adjusting for age, individuals
with 4 copies of C4 gene were more susceptible to GD
(p = 0.001, OR = 10.994, 95% CI: 6.277-19.255) as com-
pared to those without, whereas those with <4 copies of
C4 gene tended to prevent from GD (p = 0.003, OR =
0.512, 95% CI: 0.338-0.776) as compared to those with-
out. The distribution of C4A and C4B among individuals
with or without GD was further investigated. For C4A
gene, individuals with 2 copies of C4A increased the risk
toward GD (p = 0.008, OR = 1.732, 95% CI: 1.190-2.520)
whereas those with <2 copies of C4A reduced the risk
toward GD (p = 0.01, OR = 0.584, 95% CI: 0.360-0.948).
For C4B gene, individuals with 2 copies of C4B increased
the risk toward GD (p = 2.420 × 10-5, OR = 2.621, 95%
CI: 1.791-3.835) whereas those without 2 copies of C4B
reduced the risk toward GD (p = 0.008, OR = 0.487, 95%
CI: 0.322-0.738 for those with <2 copies C4B; p = 0.015,
OR = 0.545, 95% CI: 0.347-0.856 for those with >2 copies
C4B respectively). Polymorphism analysis indicated tat
individuals with the most common polymorphism
(37.3%), A2B2, with 2.671-fold risk toward GD (p = 1.395
× 10-4, OR = 2.671, 95% CI: 1.761-4.052) as compared to
Liu et al. Journal of Biomedical Science 2011, 18:71
http://www.jbiomedsci.com/content/18/1/71
Page 2 of 8
Table 1 Background and demographic characteristics of patients with Graves’ disease
Patients’ characteristics Healthy (160) GD (624) Myxedema P-value GO P-value Vitiligo P-value
No Yes No Yes No Yes
Age at diagnosis
≤ 40 145 (90.6) 307 (49.2) 247 (47.0) 59 (60.2) 0.017 182 (45.8) 125 (55.1) 0.027 239 (46.9) 68 (59.6) 0.014
> 40 15 (9.4) 317 (50.8) 278 (53.0) 39 (39.8) 215 (54.2) 102 (44.9) 271 (53.1) 46 (40.4)
Gender
Male 32 (20.0) 133 (21.3) 110 (21.0) 22 (22.4) 0.739 74 (18.6) 59 (26.0) 0.031 107 (21.0) 26 (22.8) 0.700
Female 128 (80.0) 491 (78.7) 415 (79.0) 76 (77.6) 323 (81.4) 168 (74.0) 403 (79.0) 88 (77.2)
Treatment
Radioiodine
No 601 (96.3) 504 (96.0) 96 (98.0) 0.345 389 (98.0) 212 (93.4) 0.003 489 (95.9) 112 (98.2) 0.226
Yes 23 (3.7) 21 (4.0) 2 (2.0) 8 (2.0) 15 (6.6) 21 (4.1) 2 (1.8)
Thyroid gland surgery
No 564 (90.4) 472 (89.9) 91 (92.9) 0.363 363 (91.4) 201 (88.5) 0.239 457 (89.6) 107 (93.9) 0.164
Yes 60 (9.6) 53 (10.1) 7 (7.1) 34 (8.6) 26 (11.5) 53 (10.4) 7 (6.1)
Clinical features
Goiter
Grade 1-3 146 (23.5) 119 (22.8) 27 (27.6) 0.309 101 (25.5) 46 (20.4) 0.154 117 (23.1) 30 (26.3) 0.462
Grade 4-5 474 (76.5) 403 (77.2) 71 (72.4) 295 (74.5) 179 (79.6) 390 (76.9) 84 (73.7)
Nodular hyperplasia
No 483 (77.5) 434 (82.7) 49 (50.5) 2.880 × 10-12 301 (75.8) 182 (80.5) 0.175 430 (84.3) 53 (46.9) 6.670 × 10-18
Yes 140 (22.5) 91 (17.3) 49 (49.5) 96 (24.2) 44 (19.5) 80 (15.7) 60 (53.1)
Myxedema
No 525 (74.3) 305 (76.8) 220 (97.3) 1.35 × 10-11 507 (99.4) 18 (15.9) 8.900 × 10-8
Yes 98 (25.7) 92 (23.2) 6 (2.7) 3 (0.6) 95 (84.1)
Graves’ ophthalmopathy
No 397 (63.6) 305 (58.0) 92 (93.9) 1.350 × 10-11 295 (57.8) 102 (89.5) 2.200 × 10-10
Yes 227 (36.4) 220 (41.9) 6 (6.1) 215 (42.2) 12 (10.5)
Vitiligo
No 510 (81.7) 507 (96.6) 3 (3.1) 8.900 × 10-8 295 (74.3) 215 (94.7) 2.204 × 10-10
Yes 114 (18.3) 18 (3.4) 95 (96.9) 102 (25.7) 12 (5.3)

















those without. These results indicate that individuals
with 4, 2 and 2 copies of C4, C4A and C4B genes, espe-
cially those with A2B2 polymorphism may have higher
risk, whereas those with<4, <2 and ≠2 copies of C4, C4A
and C4B genes may have lower risk toward GD,
respectively.
CNV of C4 genes did not significantly associated with
myxedema and GO
We also estimated the association between polymorph-
ism of C4 genes and clinical features of GD. CNV of C4
genes showed association with susceptibility toward GO,
vitiligo and myxedema, but not goiter or nodular hyper-
plasia as estimated by Fisher’s exert test (data not
shown). After adjusting for age, nodular hyperplasia, GO,
and vitiligo, the distribution of copy number for total C4,
C4 isotypes as well as C4 polymorphisms did not associ-
ate with the occurrence of myxedema (Table 3).
The distribution of copy number for total C4, C4 iso-
types as well as C4 polymorphisms according to the pre-
sence of GO is shown in Table 4. The relationship
between C4 CNV status and GO was not significant (p =
0.396). The distribution of C4A and C4B among GD
patients with and without GO were further investigated.
After adjusting for age, gender, radioiodine treatment,
vitiligo and myxedema, neither isotypes nor polymorph-
isms of C4 was significantly associated with GO, although
GD patients with <2 copies (0 or 1) of the C4A gene were
less susceptible to GO (p = 0.014, OR = 0.549, 95% CI:
0.303-0.998) as compared to those with 2 copies of C4A,
and those with A3B1 polymorphism were less susceptible
to GO (p = 0.001, OR = 0.374, 95% CI: 0.146-0.960) as
compared to those with A2B2 polymorphism. These
results indicate that neither isotypes nor polymorphisms
of C4 was significantly associated with GO, however, as
compared to GD patients with 2 copies of C4A or those
with A2B2 polymorphism, those with <2 copies of C4A
or those with A3B1 might be protected against the devel-
opment of GO, respectively.
GD patients with <2 copies of C4A had higher risk toward
vitiligo
The distribution of copy number for total C4, C4 isotypes
as well as C4 polymorphisms according to the presence
of vitiligo is shown in Table 4. After adjusting with age,
nodular hyperplasia, GO and myxedema, patients with
Table 2 Distribution of C4 polymorphisms in individuals with or without Graves’ disease
Variations GD P value, individuala
[OR (95%CI), individual]c
P value b OR (95%CI)d
No, N (%) Yes, N (%)
C4 CNV
4 57 (35.6) 314 (50.3) 0.001 [10.994 (6.277-19.255)] 0.002 (Reference)
< 4 52 (32.5) 134 (21.5) 0.003 [0.512 (0.338-0.776)] 0.389 (0.245-0.615)
> 4 51 (31.9) 176 (28.2) 0.361 0.497 (0.317-0.780)
C4A CNV
2 83 (51.9) 395 (63.3) 0.008 [1.732 (1.190-2.520)] 0.011 (Reference)
< 2 33 (20.6) 79 (12.7) 0.010 [0.584 (0.360-0.948)] 0.509 (0.307-0.843)
> 2 44 (27.5) 150 (24.0) 0.365 0.628 (0.404-0.977)
C4B CNV
2 67 (41.9) 377 (60.4) 2.420 × 10-5 [2.621 (1.791-3.835)] 1.328 × 10-4 (Reference)
< 2 53 (33.1) 143 (22.9) 0.008 [0.487 (0.322-0.738)] 0.374 (0.240-0.584)
> 2 40 (25) 104 (16.7) 0.015 [0.545 (0.347-0.856)] 0.391 (0.241-0.636)
C4 polymorphisms
A2B2 39 (24.4) 254 (40.7) 1.395 × 10-4 [2.671 (1.761-4.052)] 3.87 × 10-6 (Reference)
A2B1 22 (13.8) 78 (12.5) 0.672 0.409 (0.219-0.763)
A3B2 16 (10.0) 64 (10.3) 0.924 0.539 (0.273-1.064)
A2B3 5 (3.1) 44 (7.1) 0.067 0.961 (0.343-2.697)
A3B1 10 (6.3) 32 (5.1) 0.574 0.373 (0.159-0.876)
A1B2 6 (3.8) 34 (5.4) 0.384 0.687 (0.257-1.836)
Other 62 (38.8) 118 (18.9) 0.242 (0.148-0.396)
Abbreviations: GD, Graves’ disease; CNV, copy number variation; OR, odds ratio; CI, confidence interval; N, number.
aIndividual C4 CNVs and polymorphisms between individuals with or without GD were evaluated by Fisher’s exact test using 2 × 2 contingency tables.
b CNV of C4, C4A and C4B between individuals with or without GD were evaluated by Fisher’s exact test using 3 × 2 contingency tables.C4 polymorphisms
between individuals with or without GD were evaluated by Fisher’s exact test using 7 × 2 contingency tables. The p value was estimated by 100,000 Monte Carlo
simulations with 99% confidence intervals (CI).
cORs and 95% CIs were estimated from logistic regression models adjusting for age.
dORs and 95% CIs were estimated from logistic regression models adjusting for age.
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<2 copies of C4A had a 5.153-fold increased risk of viti-
ligo (p = 2.650 × 10-4, OR = 5.153, 95% CI: 1.629-16.300).
It remained significant even when compared with GD
patients with 2 copies of C4A (p = 0.001, OR = 5.579,
95% CI: 1.659-18.763, Table 5). These results indicate
that <2 copies of C4A may increase the risk for vitiligo in
patients with GD.
Discussion
Several functionally relevant single nucleotide polymorph-
isms are characteristic of GD and GO [12,13], but no rele-
vant CNV has been reported [14]. In the present study, we
found that the CNV of C4, C4A or C4B may associate
with the development of GD. In addition, <2 copies of
C4A may associate with development of vitiligo in patients
with GD. To the best of our knowledge, this is the first
study to report that the linkage among CNV of C4 genes,
GD and GD-associated vitiligo. Our results provide new
information which may be applied clinically.
C4 involves in the classical pathway which is triggered
by interaction of the Fc portion of an antibody or C-reac-
tive protein with C1q. It has been shown that the copy
number of C4, C4A or C4B positively correlated with the
protein levels of total C4, C4A or C4B, respectively [7]. In
our results, individuals with 4, 2, and 2 copies of C4, C4A
or C4B have higher risk whereas those with deficiencies of
C4, C4A or C4B have lower risk toward GD. One possibi-
lity is that a deficiency of complement may lead to ineffec-
tive opsonization, lytic activity or impairment of B-cell
memory, by which reduce tissue injury [15]. Unfortu-
nately, the mechanisms by which C4 abnormality contri-
butes to the protection of organ-specific autoimmunity are
poorly understood. Nevertheless, whether a potential
gene-gene or gene-environment interaction is involved in
susceptibility to GD needs to be further investigated [16].
This study provides a substantial amount of data that may
help to clarify the role of C4 genes in this disorder. It is
only through investigations of diverse populations that
researchers can expect to dissect the complex genetics
involved. In addition, functional studies of susceptibility
genes using appropriate animal models could allow for an
assessment of their role in the disease process.
However, it may play a different regulatory role in sys-
temic autoimmune diseases. Low level of C4 comple-
ments in sera has been found in several autoimmune
diseases [17-21]. In addition, the presence of C4A null
Table 3 Distribution of C4 polymorphisms in Graves’ disease patients with or without myxedema
Variations Myxedema P value, individuala
[OR (95%CI), individual]c
P value b OR (95%CI)d
No, N (%) Yes, N (%)
C4 CNV
4 265 (50.5) 48 (49.0) 0.826 (Reference)
< 4 100 (19.0) 34 (34.7) 0.001 [1.884 (0.538-6.597)] 4.900 × 10-4 1.714 (0.447-6.575)
> 4 160 (30.5) 16 (16.3) 0.005 [0.617 (0.166-2.289)] 0.761 (0.186-3.122)
C4A CNV
2 336 (64.0) 58 (59.2) 0.364 (Reference)
< 2 57 (10.9) 22 (22.5) 0.003 [0.627 (0.164-2.404)] 0.008 0.511 (0.122-2.134)
> 2 132 (25.1) 18 (18.4) 0.159 0.496 (0.117-2.106)
C4B CNV
2 317 (60.4) 59 (60.2) 1 (Reference)
< 2 115 (21.9) 28 (28.6) 0.152 0.168 1.163 (0.298-4.542)
> 2 93 (17.7) 11 (11.2) 0.072 0.552 (0.125-2.443)
C4 polymorphisms
A2B2 217 (41.3) 36 (36.7) 0.434 0.050 (Reference)
A2B1 63 (12.0) 15 (15.3) 0.405 1.895 (0.307-11.710)
A3B2 58 (11.0) 6 (6.1) 0.202 1.371 (0.163-11.522)
A2B3 41 (7.8) 3 (3.1) 0.130 0.558 (0.029-10.789)
A3B1 26 (5.0) 6 (6.1) 0.619 0.333 (0.032-3.499)
A1B2 23 (4.4) 11 (11.2) 0.013 [1.094 (0.137-8.709)] 1.009 (0.103-9.841)
Other 97 (18.5) 21 (21.4) 0.735 (0.163-3.310)
Abbreviations: GD, Graves’ disease; GO, Graves’ ophthalmopathy; CNV, copy number variation; OR, odds ratio; CI, confidence interval; N, number.
aIndividual C4 CNVs and polymorphisms between GD patients with or without myxedema were evaluated by Fisher’s exact test using 2 × 2 contingency tables.
b CNV of C4, C4A and C4B between GD patients with or without myxedema were evaluated by Fisher’s exact test using 3 × 2 contingency tables.C4
polymorphisms between GD patients with or without myxedema were evaluated by Fisher’s exact test using 7 × 2 contingency tables. The p value was
estimated by 100,000 Monte Carlo simulations with 99% confidence intervals (CI).
cORs and 95% CIs were estimated from logistic regression models adjusting for age, nodular hyperplasia, GO and vitiligo.
dORs and 95% CIs were estimated from logistic regression models adjusting for age, nodular hyperplasia, GO and vitiligo.
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allele that results in partial C4 deficiency have shown to
be risk factor for susceptibility in systemic lupus erythe-
matosus (SLE) and the SLE-related renal damage [7,19].
A hypothesis is that complement may participate in the
presentation of self-antigens to developing B cells by
which protects against responses to self-antigens and
subsequence promoting the elimination of self-reactive
lymphocytes [9]. The pathogenesis of vitiligo, similar to
SLE, is characterized by the destruction of cutaneous
melanocytes which due to another antibody-induced
hypopigmentation. Experiments in knockout mice have
demonstrated that complement deficient can cause the
destruction of pigment cells leading to vitiligo-like depig-
mentation [21]. Our results revealed that deficiency of
C4A may enhance the development of vitiligo in GD
patients, implying exist of an alternative pathway for the
deficiency of complement.
What is interesting is that although we explored the
relationship of C4 CNV to GD as well as other GD clini-
cal features, only the lower copies of C4A, but not C4B,
were associated with higher risk of vitiligo. Because it
appears that C4A binds to amino group-containing anti-
gens such as immune complex, whereas C4B binds to
hydroxyl group-containing antigens such as bacteria, this
result may provide another view to support the hypoth-
eses that the pathogenesis of vitiligo may be more rele-
vant to the existence of the immune complex than the
pathogen. In addition, recent studies have identified that
the risk locus within the major histocompatibility com-
plex region on chromosome 6q may be associated with
vitiligo in both Chinese Han population and American
population [22,23]. It may be interesting to investigate
the gene-gene interaction between C4 polymorphism and
the vitiligo risky locus. Moreover, although confirmation
of these results in larger samples is warranted, it would
be interesting to further investigate the functional role of
C4A in the development of vitiligo.
Conclusion
This study provides evidence that the CNV of C4, C4A
or C4B may associate with the development of GD and
<2 copies of C4A may associate with development of
vitiligo in patients with GD. These results may be
further estimated for its application on predicting the
occurrence of GD and the clinical outcome in patients
Table 4 Distribution of C4 polymorphisms in Graves’ disease patients with or without Graves’ ophthalmopathy
Variations GO P value, individuala
[OR (95%CI), individual]c
P value b OR (95%CI)d
No, N (%) Yes, N (%)
C4 CNV
4 196 (49.4) 118 (52.0) 0.561 0.396 (Reference)
< 4 92 (23.2) 42 (18.5) 0.188 0.978(0.614-1.558)
> 4 109 (27.5) 67 (29.5) 0.581 1.029(0.687-1.540)
C4A CNV
2 238 (39.9) 157 (69.2) 0.025 [1.436 (0.994-2.075)] 0.014 (Reference)
< 2 61 (15.4) 18 (7.9) 0.008 [0.590 (0.328-1.059)] 0.549 (0.303-0.998)
> 2 98 (24.7) 52 (22.9) 0.628 0.772 (0.509-1.169)
C4B CNV
2 229 (57.7) 148 (65.2) 0.074 0.186 (Reference)
< 2 97 (24.4) 46 (20.3) 0.276 0.806 (0.520-1.249)
> 2 71 (17.9) 33 (14.5) 0.316 0.697 (0.430-1.132)
C4 polymorphisms
A2B2 149 (37.5) 105 (46.3) 0.035 [1.283 (0.900-1.828)] 0.005 (Reference)
A2B1 53 (13.4) 25 (11.0) 0.451 0.796 (0.449-1.411)
A3B2 37 (9.3) 27 (11.9) 0.338 1.067 (0.596-1.912)
A2B3 29 (7.3) 15 (6.6) 0.871 0.734 (0.366-1.476)
A3B1 25 (6.3) 7 (3.1) 0.091 0.374 (0.146-0.960)
A1B2 28 (7.1) 6 (2.6) 0.026 [0.451(0.176-1.160)] 0.374 (0.153-1.056)
Other 65 (16.4) 40 (17.6) 0.894 (0.549-1.455)
Abbreviations: GD, Graves’ disease; GO, Graves’ ophthalmopathy; CNV, copy number variation; OR, odds ratio; CI, confidence interval; N, number.
aIndividual C4 CNVs and polymorphisms between GD patients with or without GO were evaluated by Fisher’s exact test using 2 × 2 contingency tables.
b CNV of C4, C4A and C4B between GD patients with or without GO were evaluated by Fisher’s exact test using 3 × 2 contingency tables.C4 polymorphisms
between GD patients with or without GO were evaluated by Fisher’s exact test using 7 × 2 contingency tables. The p value was estimated by 100,000 Monte
Carlo simulations with 99% confidence intervals (CI).
cORs and 95% CIs were estimated from logistic regression models adjusting for age, gender, ever received radioiodine treatment, myxedema and vitiligo.
dORs and 95% CIs were estimated from logistic regression models adjusting for age, gender, ever received radioiodine treatment, myxedema and vitiligo.
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with GD which might aid in the diagnosis of the disease
and the development of therapeutic strategies.
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